42 results about "Embolization" patented technology

The invention discloses a cryoablation catheter system for pulmonary artery stent internal restenosis, and belongs to the field of medical instruments, the cryoablation catheter system comprises a catheter main body arranged on a guide wire, the catheter main body is provided with a treatment assembly, the treatment assembly is located at the far end of the catheter main body, the catheter main body is provided with a control handle, and the control handle is located at the far end of the catheter main body. The control handle is located at the near end of the catheter body, and the treatment assembly comprises a near-end balloon, a far-end balloon and a freezing balloon. When the near-end balloon and the far-end balloon are simultaneously full, a closed treatment cabin isolated from near-end blood flow and far-end blood flow can be formed in a blood vessel of a target treatment section, the freezing balloon is located in the treatment cabin, the closed treatment cabin thoroughly eliminates the blood flow hot pool effect, cold is prevented from being taken away by the blood flow, and the treatment effect is improved. Freezing energy is intensively acted on a diseased region, so that the ablation efficiency and accuracy are improved; meanwhile, thrombus, tissue debris and whole body blood flow which fall off in the treatment process are isolated, the risk of far-end embolism is reduced from the source, and damage to the blood vessel wall is avoided.

The application belongs to the technical field of biological detection, and discloses a cardiovascular marker control article and a preparation method thereof. The cardiovascular marker control article comprises a serum matrix, antigens, a preservative and a stabilizer. The antigens include cardiac troponin I antigens, creatine kinase isoenzyme antigens, myoglobin antigens, amino-terminal brain natriuretic peptide precursor antigens, brain natriuretic peptide antigens, D-dimer antigens, heart-type fatty acid-binding protein antigens, myeloperoxidase antigens and lipoprotein phospholipase A2 antigens. The stabilizer includes at least one of D-trehalose, sucrose, glycine, inositol and polyethylene glycol. The cardiovascular marker control article can cover various cardiovascular disease markers, including heart failure, pulmonary embolism, vasculitis and atherosclerosis, myocardial injury, myocardial infarction and the like. The control article can be used as a third-party control article for indoor and inter-laboratory quality control of a cardiovascular disease screening and auxiliary diagnosis measurement system.

The application discloses a method for constructing a 4D FLOW-based hemodynamic evaluation pulmonary embolism prognosis prediction model and application, relates to the medical image technology field, and comprises the following steps: collecting 4D-Flow images of patients who have been diagnosed with pulmonary embolism from medical institutions to obtain image data A; pre-processing the image data A, and dividing the pre-processed image data A into a training set and a verification set according to a proportion; respectively performing imageomic feature extraction, clinical feature extraction and 4D FLOW hemodynamic feature extraction on the training set and the verification set; screening the imageomic features and the clinical features and 4D FLOW hemodynamic detection indexes to obtain key features; and based on the key features, establishing a multi-omics prediction model for pulmonary embolism prognosis prediction, thereby providing a new imaging reference for pulmonary embolism treatment.

The invention belongs to the technical field of medicines, and particularly relates to application of penicillin tenuipes in preparation of a product for preventing or treating ischemic encephalopathy, cell experiments and animal experiments show that penicillin tenuipes has a good treatment effect on cerebral thrombosis and middle artery embolism, can obviously improve behavioral scores after ischemia, and can be used for preparing a medicine for preventing or treating ischemic encephalopathy. And cerebral thrombus and blood vessel diameter conditions. The penicillin tenuipes also has an anti-inflammatory effect. Therefore, the compound can be used for preparing medicines for preventing or treating ischemic encephalopathy.

Processes are provided based on an interventional (device-based) approach to minimize the development of intramyocardial hemorrhage within the myocardial infarction (MI) zone. In one exemplary process, the revascularization occurs in an incremental fashion prior to fully opening the vessel, so as to modulate the hydrostatic pressure transmitted from the proximal end of the catheter, prior to placing a stent. In another exemplary process, the stent will be placed within the central core of the embolization and will slowly expand within the lumen reaching full patency over a period of time. Devices operated with these processes can also greatly reduce the chance of development of intramyocardial hemorrhage with the MI zone. These developments can improve the outcome in hemorrhagic patients, who otherwise carry a significant risk for heart failure and sudden death.

The invention relates to the technical field of medical image processing, and discloses a liver cancer rupture bleeding embolism treatment curative effect image evaluation method and system, and the method comprises the steps: S1, obtaining enhanced CT image data of a patient after liver cancer rupture bleeding embolism treatment, carrying out the preliminary region division of a focus region of the enhanced CT image data, and carrying out the image segmentation of the focus region; obtaining a preliminary region division result; s2, when an interaction correction mark made by a user on at least one sub-region of the preliminary region division result is received, the preliminary region division result is adjusted in real time, the boundary of the adjusted sub-region is obtained, and the interaction correction mark indicates the real organization type of the sub-region; s3, circularly executing the step S2 to perform interactive iteration correction on the boundary of the sub-region until the user confirms a final division result; and S4, performing volume quantitative evaluation on different types of tissues of the final division result, and generating an evaluation report. According to the invention, misjudgment caused by fuzzy and overlapped image features is effectively avoided.

The invention relates to the technical field of health monitoring, in particular to venous thromboembolism monitoring equipment which comprises an evaluation module used for providing an evaluation scale, collecting filling information of a patient and generating a risk level evaluation result; the behavior guidance module is used for generating corresponding guidance suggestions based on the risk level assessment result, so that the patient can be protected according to the guidance suggestions; the monitoring module is used for collecting monitoring data in the protection process of the patient according to the guidance suggestions, and the monitoring data comprise leg circumference data, pain feeling data, skin color data, body temperature data, limb swelling data and pulmonary embolism expression data; and the early warning module is used for generating early warning information based on the monitoring data, and sending the early warning information to related medical personnel, so that manual monitoring is replaced by the monitoring equipment, the self-protection consciousness of the patient can be autonomously stimulated, the monitoring effect is improved, and the morbidity of venous thromboembolism is reduced.

The application provides a method and device for recommending a hepatic cancer embolism placement point planning, wherein the method comprises the following steps: obtaining input data; segmenting the input data to obtain a segmentation result of the input data, and classifying the segmentation result to determine whether there is a high-risk tumor in the liver; if there is a high-risk tumor in the liver, calculating an embolism placement point according to the segmentation result, generating an embolism placement point planning result; synthesizing the embolism placement point planning result with an original medical image to generate a recommended scheme, and outputting the recommended scheme. Through deep learning, machine learning and traditional image processing methods, various organs such as patient arterial vessels, livers, tumors and bones are automatically segmented, and according to the automatically generated segmentation information, recommended information is generated to recommend the embolism placement point of each tumor, so as to assist doctors in comprehensively and deeply understanding the condition of the patient.

The present invention relates to a solid pharmaceutical dosage form for oral administration containing (4S)-2 4 -chloro-4-ethyl-7 3 -fluoro-3 5 -methoxy-3 2 ,5-dioxo-1 4 -(trifluoromethyl)-3 2 H-6-aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzena-heptafane-7 4 -carboxamide (active ingredient (I)), characterized in that the active ingredient (I) is present in an amorphous form and is immediately released from the solid pharmaceutical dosage form for oral administration, a method for preparing the same, its use as a medicine, and its use for the treatment and / or prevention of diseases, particularly cardiovascular diseases, preferably thrombotic or thromboembolic diseases, and edema, and eye diseases. 【Chemical formula 1】 TIFF2026509613000011.tif37158

The invention relates to an application of Fgl2 gene knockout in antagonism of new coronavirus. In the technical scheme provided by the invention, a new crown infected mouse model is established through two SARS-CoV-2 mouse adaptive strains, namely, an MA17 strain and an MASCp36 strain, and it is verified that virus infection can promote Fgl2 expression up-regulation and fibrinogen deposition in mouse lung tissues; in addition, an SARS-CoV-2 mouse adaptive strain MA17 is utilized to infect an Fgl2 gene knockout mouse to prove that the Fgl2 gene knockout can antagonize lung inflammation infiltration, tissue damage, thromboembolism, fibrinogen deposition and fibrosis formation caused by virus infection, so that the occurrence of severe case and death of the mouse is reduced.

RNA interference (RNAi) agents for inhibiting the expression of Factor XI (FXI) are provided, as are pharmaceutical compositions comprising one or more FXI RNAi agents together with one or more excipients capable of delivering the RNAi agent(s) to a liver cell in vivo. Delivery of the FXI RNAi agent(s) to liver cells in vivo provides for inhibition of FXI gene expression and can provide for treatment of myocardial infarction, atrial fibrillation (AFib), deep vein thrombosis, pulmonary embolism, ischemic stroke, transient ischemic attack, retinal artery occlusion, mesenteric ischemia, renal vein thrombosis, cerebral venous sinus thrombosis, venous thromboembolism due to deep vein thrombosis, and peripheral artery disease, as well as diseases and disorders associated with angioedema, thrombosis, and / or coagulation.

The application provides a filter for breaking up thrombus. The filter comprises a power conversion mechanism, a filter support and a cutting mechanism which are connected in sequence along an axial direction and can be radially expanded and contracted; the power conversion mechanism and the cutting mechanism are axially limited and can rotate circumferentially relative to the filter support; the power conversion mechanism can convert the power of blood flow flowing from the cutting mechanism to the power conversion mechanism into rotary motion and can drive the cutting mechanism to rotate circumferentially in the filter support. According to the embodiment of the application, the cutting mechanism is driven by the power conversion mechanism to rotate circumferentially in the filter support, so that the thrombus intercepted in the filter support can be continuously cut and broken up, thereby avoiding pulmonary embolism and preventing blood vessel embolism caused by the filter for breaking up thrombus.

The application belongs to the technical field of medical devices, and particularly relates to an adhesive for treating varicose great saphenous vein and a preparation method thereof. The adhesive is obtained by the following steps: (1) preparation of poly cyanoacrylate powder; (2) preparation of the adhesive: 50-85 parts of cyanoacrylate, 5-30 parts of plasticizer, 0.01-0.5 parts of polymerization inhibitor and 0.01-0.5 parts of antioxidant are uniformly stirred, 10-30 parts of poly cyanoacrylate powder is slowly added, and stirring is continued until complete dissolution and filtration, and the adhesive is obtained. The prepared adhesive has a weight average molecular weight of 0.5-10 million, a viscosity of 500-3000 cp, low formaldehyde content, is not diluted by blood when implanted into a blood vessel, does not flow with blood, reduces the risk of ectopic embolism, reduces the risk of allergy and inflammation, and the adhesive has a curing time of less than 20 s, can quickly polymerize and form a clot to block the blood vessel when implanted into the target vein position.

The application discloses a bullet-shaped polyvinyl alcohol embolism micro-particle and a preparation method thereof, and belongs to the field of non-spherical polymer micro-particle preparation. The embolism micro-particle is made of polyvinyl alcohol, and the overall shape is bullet-shaped, with a smooth joint between a hemispherical head and a cylindrical tail. The bullet-shaped polyvinyl alcohol embolism micro-particle is continuously prepared by using microfluidic technology, and the steps are as follows: (1) preparing modified polyvinyl alcohol macromolecules; (2) preparing a dispersed phase fluid, a continuous phase 1 fluid and a continuous phase 2 fluid; (3) preparing bullet-shaped non-spherical micro-particles by using a two-stage microfluidic device; and (4) storing the washed bullet-shaped polyvinyl alcohol embolism micro-particles in pure water. The bullet-shaped polyvinyl alcohol embolism micro-particle prepared by the application can effectively improve the flow characteristics and movement rate of the micro-particle in a channel, thereby improving the embolism effect of the micro-particle, and has important clinical application value for tumor embolism treatment.

Disclosed herein are devices, systems, and methods useful in facilitating the removal of thrombus, embolus, or debris from a blood vessel and other intravascular interventional actions, including proximal embolic protection when treating a vascular lesion or condition.

Novel direct thrombin inhibitors are provided herein, along with methods for their use as anticoagulants. The direct thrombin inhibitors described herein are useful in treating and / or preventing thromboembolism and bleeding or clotting disorders. Also provided herein are methods for inhibiting thrombin in a cell using the compounds and compositions described herein.

Disclosed herein are clot treatment systems including an integrated / systematic mechanical thrombectomy device and a clot treatment device, and associated devices and methods. In some embodiments, a method of removing clot material from a blood vessel of a patient includes inserting a catheter within the blood vessel proximate the clot material while radially constraining a clot handling device and an embolic protection device within the catheter. The method may also include moving the catheter proximally to at least partially deploy the clot treatment device to a distal side of the clot material within the blood vessel, and then further moving the catheter proximally to at least partially deploy the embolic protection device to a proximal side of the clot material.

The invention provides an embolism microsphere for chronic musculoskeletal system pain control and a preparation method and application thereof, and belongs to the technical field of medicine. The polysaccharide-absorbable embolism microsphere is prepared by effectively wrapping antibiotic particles inside the polysaccharide-absorbable embolism microsphere. After the embolism microsphere reaches a target blood vessel, the antibiotic particles can be slowly released along with degradation of the polysaccharide microsphere, and the embolism microsphere provided by the invention is simple in preparation process, easy for large-scale production and capable of better meeting clinical use requirements.

The present invention covers the use of chymase inhibitors in general and more in particular substituted bicyclically substituted uracils of general formula (I) as described and defined herein, and 3-methylbenzo-[b]thiophene)-2-sulfonamido derivatives of general formula (II) for manufacturing pharmaceutical compositions for the treatment or prophylaxis of stroke, pulmonary embolism, deep or superficial vein thrombosis, thrombotic microangiopathy, thrombotic microangiopathy in hypercoagulable states after infection, inflammation, transplantation, disseminated intravascular coagulation, vaccine-induced immune thrombotic thrombocytopenia, vascular access site thrombosis or occlusion.

Cardiac arrest (CA) and traumatic brain injury (TBI) are critical medical events associated with high mortality and long-term disability, primarily due to ischemia and subsequent inflammation. Targeted temperature management (TTM), particularly hypothermia, has proven beneficial in reducing cell death, preserving brain function, and mitigating inflammation following these events. Conventional TTM methods are limited by delayed temperature reduction, poor temperature maintenance, and risks such as thromboembolism. The present invention addresses these challenges by introducing novel devices, apparatus, and systems for extracorporeal whole blood cooling, enabling rapid, controlled induction and maintenance of therapeutic hypothermia. By efficiently cooling the patient's whole blood volume outside the body, the method of the present invention offers a safer, more effective alternative to traditional methods, significantly improving patient outcomes after events such as CA and TBI. The present invention represents a promising advancement in emergency and critical care, enhancing survival and neurological recovery in severely ill patients.

RNA interference (RNAi) agents for inhibiting the expression of Factor XI (FXI) are provided, as are pharmaceutical compositions comprising one or more FXI RNAi agents together with one or more excipients capable of delivering the RNAi agent(s) to a liver cell in vivo. Delivery of the FXI RNAi agent(s) to liver cells in vivo provides for inhibition of FXI gene expression and can provide for treatment of myocardial infarction, atrial fibrillation (AFib), deep vein thrombosis, pulmonary embolism, ischemic stroke, transient ischemic attack, retinal artery occlusion, mesenteric ischemia, renal vein thrombosis, cerebral venous sinus thrombosis, venous thromboembolism due to deep vein thrombosis, and peripheral artery disease, as well as diseases and disorders associated with angioedema, thrombosis, and / or coagulation.

A preparation method of a particle hydrogel includes: mixing a gelatin nanoparticle, a calcium carbonate nanoparticle, an iron oxide nanoparticle, and a sodium alginate solution under alkaline conditions, and adding GDL to produce the particle hydrogel with improved mechanical properties, which is abbreviated as Ca-Alg / MCG. The present disclosure endows the hydrogel system with properties such as catheter injectability, vascular deliverability, and intravascular hardenability. The particle hydrogel can be delivered to fine blood vessels of tumors. The mechanical properties of the particle hydrogel can be gradually enhanced over time, which further improves the embolization efficacy of the particle hydrogel in blood vessels. Magnetic nanoparticles endow the particle hydrogel with magnetothermal responsiveness. Thus, the particle hydrogel can undergo a rapid temperature rise under an alternating magnetic field to further kill tumor cells. The particle hydrogel demonstrates improved embolization efficacy in rabbit renal embolization models and rabbit liver cancer-embolization models.

This invention discloses a method and system for constructing an AI-assisted diagnostic agent for pulmonary embolism based on ontology and knowledge graph, belonging to the fields of medical information systems and medical artificial intelligence technology. By integrating a pulmonary embolism-specific medical ontology, a clinically aligned knowledge graph, and thought chain reasoning, this invention leverages the hard constraints of ontology knowledge to achieve interpretability analysis of the entire process of AI-assisted diagnosis for pulmonary embolism, precise suppression of AI illusions specific to pulmonary embolism, end-to-end quality control, and closed-loop optimization. It is particularly suitable for rapid diagnosis of acute and critical pulmonary embolism, AI-assisted identification of pulmonary artery filling defects in CTPA images, thrombosis severity stratification, and emergency treatment decision tracing and regulatory compliance quality control scenarios. It can be adapted to the implementation, regulatory verification, and clinical optimization of various pulmonary embolism AI imaging diagnostic and emergency auxiliary diagnosis and treatment systems, specifically addressing core illusion problems in pulmonary embolism AI diagnosis such as false positive embolus identification and disordered risk stratification.

The invention belongs to the technical field of medical instruments, and provides a spring ring with an embolism effect and a controllable degradation characteristic and a using method thereof.The method comprises the steps that blood vessel data are collected through medical imaging equipment, and the collected blood vessel data are input into a preset intelligent algorithm model; analyzing blood vessel data and outputting adaptive spring ring diameter, length and degradation period parameters; in an interventional operation, implantation track data of a spring ring are obtained in real time by means of a development marking technology, image data are analyzed synchronously, and information for adjusting the implantation angle and depth is generated; postoperative data of the degradation state of the spring ring and the healing condition of the blood vessel are regularly obtained through image examination after the operation, the obtained postoperative data are dynamically analyzed, whether the corresponding degradation progress accords with a preset period or not is judged, and if degradation abnormity occurs, intervention suggestion information is generated until the spring ring is completely degraded and the normal physiological function of the blood vessel is recovered.

This invention relates to the field of composite material preparation technology, specifically to a high-mechanical-performance particulate hydrogel, its preparation method, and its applications. The method involves mixing gelatin nanoparticles, calcium carbonate nanoparticles, iron oxide nanoparticles, and sodium alginate solution under alkaline conditions, followed by the addition of gluconate-δ-lactone to prepare a high-mechanical-performance particulate hydrogel, abbreviated as Ca-Alg / MCG. This hydrogel system possesses properties suitable for catheter injection, vascular delivery, and intravascular hardening. The hydrogel can be delivered to the small blood vessels of tumors, and its mechanical properties gradually increase over time, further enhancing its embolizing effect in blood vessels. Simultaneously, the magnetic nanoparticles endow the hydrogel with magnetothermal responsiveness, allowing it to rapidly heat up under an alternating magnetic field, further killing tumor cells. Excellent embolizing effects have been observed in rabbit kidney embolization models and rabbit liver cancer embolization models.

The application relates to the technical field of image processing, and discloses a pulmonary embolism lesion segmentation method and system based on image recognition and a storage medium. The method comprises the following steps: extracting a multi-level blood vessel topological structure of a CTPA image through blood vessel diameter gradient analysis; modeling blood vessel density distribution by using a Weibull mixed model to obtain an embolism characteristic parameter; estimating a pixel embolism probability by using variational Bayesian inference to generate a lesion distribution map; performing multi-scale feature fusion on the lesion probability map to obtain a segmentation boundary; and optimizing the boundary based on blood vessel connectivity constraints to obtain a final embolism lesion segmentation result. The application solves the problems that blood vessel level differentiation processing cannot be realized, accurate probability modeling is lacked, and anatomic constraint verification is lacked. The application improves the precision of pulmonary embolism lesion segmentation.

The invention discloses a medicine for treating atrial fibrillation in an acute exacerbation stage of a chronic obstructive pulmonary disease and a preparation method of the medicine. The medicine is prepared from raw rhizoma coptidis, raw fructus gardeniae, lophatherum gracile, radix ophiopogonis, radix rehmanniae recen, lily, codonopsis pilosula, radix salviae miltiorrhizae, moutan bark, radix paeoniae rubra, semen boitae, spina date seeds, poria with hostwood and raw liquorice. The traditional Chinese medicine composition has the effects of clearing away heart fire and nourishing heart yin, has the effects of cooling and activating blood and clearing away heart fire and tranquilizing mind, and is suitable for atrial fibrillation in the acute exacerbation stage of chronic obstructive pulmonary disease, assisting in controlling the ventricular rate, preventing and treating thromboembolism and promoting the atrial fibrillation rhythm to be converted into sinus normal rhythm.

The application relates to a postoperative embolism syndrome monitoring method and system for a liver cancer patient, which comprises the following steps: acquiring multi-dimensional time sequence clinical data of the patient, interpolating missing values of the data through a probability regression model and generating uncertainty estimation for each interpolation point, constructing derived features based on the interpolated data, namely, calculating a time sequence change rate gradient of at least one core biochemical index and a time attenuation weighted fluctuation value of at least one vital sign index by taking the reciprocal of the uncertainty estimation as a weight, training a tree structure ensemble learning early warning model by using an asymmetric cost-sensitive loss function which is fused with a category imbalance penalty factor and a sample-specific weight determined by the time sequence change rate gradient of positive samples, inputting patient data to be warned into the trained model to output a risk probability, and triggering a high-level risk warning when the risk probability exceeds a preset threshold and key contribution features in model explainability analysis contain core inflammatory indicators as a subset of core biochemical indicators.

The application provides an anti-embolism filter manufacturing method and an anti-embolism filter. The method comprises the following steps: step one, performing hole processing treatment on a polymer film to form a filter film with filter holes; step two, providing a stent for an interventional operation; and step three, performing solidification treatment on the filter film and the stent to form an anti-embolism filter. The anti-embolism filter manufactured by the method has filter holes that can cover the entire filter film, and the porosity and consistency are improved, so that the blood flow circulation and the capture of thrombus particles can be considered during the interventional operation.

The invention discloses a blood vessel blood stasis removing and dredging pill for treating cardiovascular and cerebrovascular diseases. The blood vessel blood stasis removing and dredging pill is prepared from astragalus membranaceus, dog bone meal, sheep bone meal, radix paeoniae rubra, cortex moutan, safflower carthamus, edgeworthia chrysantha, calamitas urinae hominis, lumbricus, angelica sinensis, plant soot, arrowhead, kelp, celery seeds, rhizoma zingiberis and honey-fried licorice root. The traditional Chinese medicine can be used for effectively treating cardiovascular and cerebrovascular diseases, eliminating originally formed clogging and embolism of blood vessels, removing conditions and inducements of clogging and embolism formation from a pathological formation mechanism, effectively preventing new clogging and embolism formation of the blood vessels, and is excellent in overall effective rate.